Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.

Andrea LoehrAkash PatnaikDavid CampbellJeremy ShapiroAlan H BryceRay McDermottBrieuc Sautois Nicholas J VogelzangRichard M BamburyEric VoogJingsong ZhangJosep M PiulatsArif HussainCharles J RyanAxel S MerseburgerGedske Daugaard Axel HeidenreichKarim FizaziCelestia S HiganoLaurence E KriegerCora N Sternberg Simon P WatkinsDarrin DespainAndrew D SimmonsMelanie DowsonTony GolsorkhiSimon ChowdhuryWassim Abida

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA+ mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
squamous cell carcinoma
chronic kidney disease
dna damage
peritoneal dialysis
prognostic factors
gene expression
copy number
breast cancer risk
replacement therapy
smoking cessation
combination therapy
wild type